DIVI S LABORATORIES LTD
Indian maker and seller of generic active pharmaceutical ingredients (APIs), intermediates and nutraceuticals.
Also does custom synthesis contract manufacturing.
Sells in India, North America, Asia and Europe.
Overview
Strengths
- Shows the financial signature of a durable competitive advantage (economic moat): returns well above its cost of capital, high, stable gross margins (pricing power) and operating margins that held up every year.
- Creates economic value: ROIC of 16.3% against a cost of capital (WACC) of 7.1%, a spread of 9.2 percentage points.
- Pricing power: gross margin has held between 58% and 59% over the last 4 years (latest 59.1%).
- Consistent growth: revenue has compounded at 11.0% a year over 3 years, rising every year.
- EBITDA margin of 37.6% beats 85% of its 55 Drug Manufacturers - Specialty & Generic peers (median 22.4%).
- Net cash balance sheet: cash exceeds total debt.
Weaknesses
- Our discounted cash flow target price (155.88 INR) is 98% below the current price.
- Capital-intensive: capital expenditure absorbs 15% of revenue, leaving free cash flow at only 33% of net income.
- Valued at a premium to its Drug Manufacturers - Specialty & Generic peers: EV/EBITDA 67.5x vs. a median of 12.5x.
- More expensive than its own history: EV/EBITDA 67.5x vs. a historical average of 39.0x.
Key Financial Data